A Study to Evaluate the Impact of Liquid Biopsy in Participants With a Clinical Diagnosis of Advanced Cancer

Inclusion Criteria:

• Participants presenting with a clinical diagnosis of advanced cancer, falling intoone of the following two clinical presentations: i) De novo metastatic lung cancer as evidenced by imaging demonstrating a lungnodule/mass and objective evidence of a metastatic process; OR, ii) De novometastatic gastrointestinal cancer as evidenced by imaging demonstrating ametastatic process in the abdomen/pelvis

• Participants who are treatment naïve for the metastatic setting under study

• Ability to comply with the study protocol

• Participants must either: i) Have a tissue biopsy intended/planned to confirm malignant disease and histology;OR, ii) Have a tissue biopsy already performed but pathology has not yet beenfinalized.

If a tissue biopsy has already been performed prior to ICF signature, then the subtyping of primary tumor may have already been assessed (i.e., for lung cancer TTF1, p40, and napsin A IHC staining may have already been performed).

Exclusion Criteria:

• Participants deemed not fit for treatment with systemic therapy

• Participants deemed not fit for tissue biopsy

• Participants with hematological neoplasm

• Participants with primary malignant neoplasm of the brain

• Participants with any previous molecular testing (NGS or other methods) e.g., allimmunohistochemistry staining recommended by ESMO aiming to define the treatmentdecision (i.e., for lung cancer ALK, EGFR, and PD-L1 IHC staining must not havealready been performed). Participants in which tissue biopsy and primary histotypinghave been performed can be included in the study.

• Prior treatment for metastatic cancer with the exception of participants who havealready been diagnosed and treated for cancer, other than the cancer type understudy, who have no evidence of relapse

• History of malignancy within 5 years prior to screening, with the exception of thecancer under investigation in this study and malignancies with a negligible risk ofmetastasis or death (e.g., 5-year overall survival rate > 90%), such as adequatelytreated carcinoma in situ of the cervix, non-melanoma skin carcinoma, localizedprostate cancer, ductal carcinoma in situ, or Stage I uterine cancer